Benitec Biopharma公布BB-301 Ib/IIa期临床试验积极长期研究结果:疗效显著且持续应答持久

美股速递
Jan 11

Benitec Biopharma Limited(BNTC)近日公布了其候选疗法BB-301在Ib/IIa期临床试验中的长期随访数据,结果显示该疗法不仅表现出强劲的治疗效果,而且患者应答显示出持续的持久性。这一积极数据进一步验证了该疗法在目标适应症中的治疗潜力,为后续临床开发提供了有力支持。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10